Free Trial

Surmodics Q2 2024 Earnings Report

Surmodics logo
$36.88 +0.24 (+0.66%)
As of 01/17/2025 04:00 PM Eastern

Surmodics EPS Results

Actual EPS
$0.07
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.43
One Year Ago EPS
-$0.40

Surmodics Revenue Results

Actual Revenue
$31.96 million
Expected Revenue
$28.79 million
Beat/Miss
Beat by +$3.17 million
YoY Revenue Growth
N/A

Surmodics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Surmodics Earnings Headlines

SurModics (SRDX) Gets a Hold from Lake Street
WARNING: “Buffett Indicator” flashing for first time in 50 years
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
See More Surmodics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surmodics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surmodics and other key companies, straight to your email.

About Surmodics

Surmodics (NASDAQ:SRDX), together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

View Surmodics Profile

More Earnings Resources from MarketBeat